Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Annamycin + Cytarabine in Refractory/Relapsed AML
NCT06788756Phase 3Recruiting
- Sponsor
- Moleculin Biotech, Inc.
- Start
- Mar 2025
- Primary completion
- Aug 2029
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) (5 arms), sponsored by Moleculin Biotech, Inc. Primary endpoints: Determination of Optimal Dosage Regimen at 49 days and Expansion at Optimal Dosage Regimen at 49 days. Started Mar 2025; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06788756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788756.